Prospective, open, multi-center, double arm clinical trial evaluating the efficacy of ultra low dose of decitabine in myelodysplastic syndromes (MDS)
Phase of Trial: Phase IV
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 07 Nov 2017 Planned End Date changed from 28 Feb 2018 to 1 Aug 2019.
- 07 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2019.
- 22 Jun 2016 Status changed from not yet recruiting to recruiting.